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Primary splenic angiosarcoma is an extremely rare and aggressive neoplasm of the vasculature. Uniformly, primary
splenic angiosarcoma is a fatal disease despite early diagnosis and treatment. Only patients with localized disease
amenable to surgical resection achieve long-term, disease-free survival. We present a review of the literature and
report a case of a 3-year-old girl with metastatic primary splenic angiosarcoma who was offered aggressive surgical
and medical treatment with curative intent despite her advanced presentation.
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Primary splenic angiosarcoma (PSA) is an extremely rare
and aggressive neoplasm of the vasculature that occurs
in adults and children. Uniformly, PSA is a fatal disease
despite early diagnosis and treatment. To date, only
patients with localized disease amenable to surgical resec-
tion are likely to achieve long-term, disease-free survival.
In this review, we summarize the literature and report a
case of a 3-year-old girl with metastatic PSA who was
offered aggressive surgical and medical treatment with
curative intent despite her advanced presentation. Follow-
ing splenectomy, our patient was given a gemcitabine-
docetaxel chemotherapeutic regimen, which has never
been described before in children with PSA. This
treatment regimen achieved a partial response and was
followed by liver metastasectomy. This enabled us to
render her free of any gross disease and allowed her to
undergo the living-related liver transplantation evalu-
ation as a viable curative option.* Correspondence: oserrano@montefiore.org
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We report on a previously healthy 3-year-old girl who
presented with complaints of abdominal pain and dis-
tention, and decreased oral intake in the setting of high
fevers. On physical examination, she was found to have
massive splenomegaly. Her laboratory work-up was sig-
nificant for anemia and mild thrombocytopenia. An
abdominal X-ray showed a markedly enlarged spleen with
displacement of bowel and an abdominal ultrasound
revealed several hyperechoic nodules in an enlarged
spleen. This prompted magnetic resonance imaging (MRI)
of the abdomen which showed massive splenomegaly with
central hemorrhage and multiple nodular lesions in the
liver (Figure 1).
Fearing splenic rupture in the setting of hemodynamic
decompensation, an emergent splenectomy was performed.
Intraoperatively, she was noted to have a massively enlarged
multinodular spleen, gross nodular lesions on her liver, a
minimal amount of ascites, and no evidence of further
organ involvement. Pathologic examination revealed an
enlarged, nodular spleen with a central hemorrhagic com-
ponent (Figure 2). Histologic examination revealed findings
consistent with high-grade angiosarcoma (Figure 3) and the
diagnosis of PSA was confirmed with additional stains for
smooth muscle actin and CD34 (Figure 4). Cytology from
the peritoneal fluid was negative for malignant cells.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Axial pre- and post-contrast T1-weighted magnetic
resonance images. The pre-contrast T1-weighted image demonstrates
an enlarged spleen with a small area of high signal in the periphery,
suggestive of focal hemorrhage. Pre-contrast T1-weighted images also
demonstrate three small hypointense hepatic lesions in both lobes of
the liver, which show avid enhancement following administration of
intravenous contrast. Bottom. Post-contrast T1-weighted images of the
spleen demonstrate nearly complete replacement of the spleen by the
tumor and by multiple areas of necrosis.
Figure 2 Gross multinodular spleen specimen. The tumor is not a
well circumscribed mass but rather a diffuse process replacing the entire
spleen, therefore a definitive size is difficult to determine. The spleen
weighed 540 g and measured 17 × 12 × 45 cm in overall dimensions.
Serrano et al. World Journal of Surgical Oncology 2014, 12:379 Page 2 of 7
http://www.wjso.com/content/12/1/379Her post-operative work-up included positron emission
tomography-computed tomography (PET/CT), which
revealed fluorodeoxyglucose-avid disease exclusive to
the liver (Figure 5). Given the diffuse, nodular infiltration
of the liver, her disease was deemed unresectable and she
was offered chemotherapy. She was treated with a total of
eight cycles of gemcitabine and docetaxel as described by
Rapkin and colleagues [1]. A repeat MRI after cycle 5
demonstrated a decrease in the size and number of the
liver lesions. Five months after her splenectomy, she
underwent a wedge liver biopsy to evaluate her metastatic
disease. The pathology revealed extensive necrosis with
foci of viable tumor cells consistent with a partial response
to chemotherapy (Figure 6).
After extensive discussion in our multidisciplinary tumor
board, and given her favorable response to chemotherapy,
the option of living-related liver transplantation was madeavailable to the family as a means to render the patient
disease-free. However, during the transplant evaluation
time period, the patient had clinical deterioration and was
admitted to the hospital with worsening abdominal pain
and distention. She was found to have bilateral pleural
effusions and extensive ascites. Liver failure rapidly ensued
and, within days of her admission, her family opted for
comfort care measures. She died shortly thereafter.
Discussion
First described by Theodor Langhans in 1879 [2], PSA is
among the rarest forms of cancer with a reported inci-
dence between 0.14 and 0.25 per million persons [3,4].
The median age of diagnosis is 63 years old and, to date,
only seven pediatric cases of PSA have been described in
the literature (Table 1) [5-11]. A number of environmental
agents or predisposing conditions have been associated
with the development of PSA in adults, including expos-
ure to ionizing radiation [10], prior chemotherapy for
lymphoma [12], or the presence of benign tumors of the
spleen - namely hemangiomas or hemangioendotheliomas
[5]. However, given its scarce incidence, it is difficult to
definitively isolate risk factors.
To date, only two case series have been published that
describe the pathologic behavior of PSA on a combined
68 adult patients [3,4]. However, clinical and pathologic
characteristics can be gleaned from these small studies.
Patients commonly present with abdominal pain (83%)
and splenomegaly (92%). Constitutional symptoms are
not generally a characteristic of PSA, with only 40% of
patients exhibiting weight loss, 10% experiencing fevers,
and 5% complaining of fatigue. A small minority of patients
(13%) will present with splenic rupture which is uniformly
considered a grave prognostic factor given the high prob-
ability of widely disseminated disease. Hematologic analysis
Figure 3 Histologic examination revealed findings consistent
with high-grade angiosarcoma. (A) Medium power view showing
anastomosing vascular channels lined by highly atypical cells (200×).
(B) Medium power view showing numerous mitoses with one
highlighted by the arrow (200×).
Figure 4 The diagnosis of primary splenic angiosarcoma was
confirmed with additional stains for smooth muscle actin and
CD34. (A) Low power view of strongly positive CD34 stain (100×).
(B) Low power view of smooth muscle actin stain, which highlights
the vascular architecture (100×).
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cytopenia, including anemia (49%), thrombocytopenia
(25%), or pancytopenia (23%), while a small minority of
patients exhibit leukocytosis (18%) [3,4]. It is unclear
whether these features are direct manifestations of the
disease or simply indirect correlations of splenomegaly.
Histologically, angiosarcomas are rapidly proliferating,
highly infiltrating anaplastic tumors that recur locally,
spread widely, and have a propensity for rapid lymph
node and systemic dissemination [3,4,13]. They arise from
splenic vascular endothelium and mesenchymal-derived
elongated endothelial cells lining the spleen’s spongy sinus-
oidal network [13]. Their immediate access to the reticulo-
endothelial system and their location of origin may in part
explain the aggressive nature and behavior of PSA. On
gross examination, spleens often weigh >1,000 grams [3].
Macroscopic examination reveals a diffuse replacement
of splenic parenchyma by tumor [13]. Microscopically,
PSA has a characteristic vascular channel formation with
carcomatous stroma [14]. The tumor itself consists of dis-
organized anastomosing vascular channels lined by large,atypical endothelial cells with significant irregular, hyper-
chromatic nuclei (Figure 3) [13]. Several reports of PSA
have described massive splenic calcifications as a feature
of the disease [15,16]; however, calcifications can also
be found in benign processes, making it a nonspecific
characteristic for malignancy.
Radiologic features of PSA can range from ambiguous
lesions to highly aggressive-appearing tumors in the
spleen, often with concomitant metastases at the time of
diagnosis [17]. Ultrasound findings of PSA are nonspe-
cific in the majority of cases, but it is usually the first
diagnostic test performed in children. The most common
ultrasound findings are splenomegaly, splenic heterogen-
eity, and poorly defined solid and cystic lesions [17]. Areas
of hemorrhage and necrosis within the tumor are fre-
quently seen as cystic lesions. Increased Doppler flow may
be seen in the more solid echogenic portions of the tumor
[18]. On CT, the most common appearance is that of a
heterogeneous lesion with areas of low density and
necrotic degeneration [17]. Non-contrast CT images may
Figure 5 Positron emission tomography-computed tomography
(posterior view) confirms diffuse small areas of uptake in the
hepatic parenchyma consistent with metastatic disease to the liver.
Figure 6 Histologic examination of wedge liver biopsy. (A) Low
power (2×) view of metastatic liver lesion showing area of necrosis
and hemosiderin with a small focus of viable tumor remaining at
the periphery of the specimen. (B) Low power (4×) view showing
area of necrosis and hemosiderin with no viable tumor remaining.
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rhage or calcifications from the hemosiderin deposits [19].
Images performed with intravenous contrast show marked
heterogeneous enhancement, necrosis, and hemorrhage.
CT evidence of dense ascites is highly suggestive of the
spontaneous hemorrhage from splenic rupture. Hyper-
vascular metastatic deposits have been reported in the
literature [6,17]. Most of these are found in the liver,
but they have also been described in the lungs, bones
and lymphatic organs. The MRI appearance of PSA
depends on the extent of the hemorrhage and necrosis
in the tumor. Areas of increased and decreased signal
intensity may be seen on images obtained with both
T1- and T2-weighted pulse sequences depending on
the presence of blood products and necrosis [17].
Multiple studies on angiosarcomas have reported the
lack of association between histological appearance or
grade with survival [20]. It appears that small tumor size
(<5 cm) exclusively favors a better prognosis [20]. A
multivariate analysis of 55 adult patients with cutaneous
and solid-organ angiosarcomas reported mitotic count,
Table 1 Published cases of pediatric primary splenic angiosarcoma
Report Age Sex Metastasis Reported survival
Alt et al. [5] 14 months M Liver, lung 3 months
den Hoed et al. [6] 2 years F Liver 30 months
Ferrara et al. (1955) [7] 15 years F Liver
Hsu et al. [8] 7 years M None 16 years
Kren et al. [9] 15 years M Liver <1 month
Serrano et al. (2014; present study) 3 years F Liver 8 months
Sordillo et al. (1983) [10] 12 years F Liver, bone, bone marrow <1 month
Wick et al. [11] 13 years M Liver, bone, serosal surfaces, skin 10 months
F, female; M, male.
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able prognostic factors [9]. Ultimately, early detection and
prompt surgical management is the best approach to
prevent splenic rupture, which yields the best chance for
survival. Splenectomy prior to splenic rupture has been
reported to offer a survival advantage with a mean survival
time of 14.4 months versus 4.4 months after rupture [21].
The prognosis for patients with PSA is grim. In the
two major case series that examined the behavior of
PSA, the overwhelming majority of patients presented
with advanced disease [3,4]. The 6-month overall survival
after diagnosis is less than 25%. In the pediatric popula-
tion, survival has been reported from less than 1 month to
16 years (Table 1). The majority (69 to 100%) of patients
with PSA present with metastasis, most commonly to the
lungs (78%), liver (63%), bone (31%), and lymph nodes
(27%) [3,4]. These statistics highlight the importance of
early surgical intervention in an attempt to achieve long-
term disease-free survival [3,4,8,9].
Owing to the rarity of PSA in the pediatric population,
the choice of treatment regimen on this particular case was
based on the adult angiosarcoma literature. Case reports
in adults, while lacking large cohorts of patients, seem
to indicate that patients with angiosarcoma respond to
gemcitabine and docetaxel, or to other taxanes [11,22,23].
The combination regimen of gemcitabine and docetaxel
has been shown to be effective in the treatment of various
malignancies, including non-small cell lung cancer, breast
cancer, and advanced uterine leiomyosarcoma [24-26].
A phase II trial also showed efficacy of this regimen in
various metastatic soft tissue sarcomas in adults when
compared with gemcitabine alone [27], and, albeit scarce,
there is some evidence to suggest that this combination is
effective in pediatric soft tissue sarcomas [1,27].
A retrospective review conducted by Leu and col-
leagues examined 35 patients with bone and soft tissue
sarcomas, including four patients with angiosarcoma [25].
Some patients had previously received chemotherapy,
mainly with doxorubicin and/or ifosfamide - a combin-
ation often used as first-line therapy in various soft tissue
sarcomas - and some received gemcitabine and docetaxeldue to the toxicity of the doxorubicin/ifosfamide regimen.
Of the angiosarcoma patients, two had a complete re-
sponse to therapy, one had partial response, and one had
stable disease. The patients who had a complete response
were chemotherapy-naïve while the others were not.
Additional clinical trials have demonstrated the efficacy
of other taxanes at treating angiosarcomas. Penel and col-
leagues enrolled 30 patients with metastatic or unresect-
able angiosarcomas in a Phase II clinical trial examining
the efficacy and toxicity of weekly paclitaxel [22]. Eight
patients had locally advanced unresectable disease; 22
patients had metastatic disease. On this regimen of weekly
paclitaxel, the non-progression rate was 74% at 2 months
and 42% at 4 months. Overall survival was 56%, 38%, and
21% at 6, 12, and 18 months, respectively. Of interest,
after weekly paclitaxel treatment, three patients with local
disease showed a complete histological response that
made curative-intent surgery feasible [22].
The seven pediatric patients previously described in the
literature with the addition of the patient in this case are
listed in Table 1 [5-11]. Similar to their adult counterparts,
the pediatric patients rarely presented with localized
disease, with only one of the eight patients demonstrating
disease localized to the spleen. All the rest presented with
metastatic disease. Every patient presenting with metas-
tases had liver involvement. Three patients had involve-
ment of other viscera: lung (1), bone (2), bone marrow (1),
serosal surfaces (1), and skin (1).
Two of the eight pediatric patients achieved durable
remission. The patient with disease limited to the spleen
was treated by splenectomy without adjuvant therapy. The
patient described by den Hoed and colleagues presented
with splenic rupture and liver metastases [6]. She was
treated with ifosfamide, vincristine, and actinomycin D for
nine cycles with radiographic improvement in the size and
number of the liver lesions. After 5 months of observation,
two lesions increased in size which prompted wide resec-
tion with partial hepatectomy: pathology revealing viable
tumor. She received three additional cycles of similar
chemotherapy and there remained no evidence of disease
at 30 months. Our patient likewise demonstrated radio-
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When the liver lesions were biopsied, they revealed
primarily necrosis with small pockets of viable tumor.
The lesions in the liver subsequently progressed rapidly
while awaiting evaluation for liver transplantation. She
never developed involvement of her other viscera. Three
other patients with metastatic disease were treated with a
combination of splenectomy and chemotherapy. All of
them succumbed to their disease with a range of a few
weeks to 10 months.Conclusion
PSA is an extremely rare and aggressive neoplasm of the
vasculature that has a very poor prognosis. We present an
aggressive multidisciplinary approach in a 3-year-old girl
with metastatic PSA who was treated with splenectomy,
liver metastasectomy, chemotherapy, and an attempt to
liver transplantation. This case report and review of the
literature reveals that angiosarcoma in children may be
chemo-responsive in some cases. However, this case also
illustrates that, in patients with gross disease, surgical
extirpation of the primary neoplasm and all metastases is
necessary to achieve durable remission. Furthermore, this
case underscores the importance of an aggressive multi-
disciplinary team approach in these complicated cases
aiming for a cure.Consent
Written informed consent was obtained from the patient’s
family for publication of this case report and any accom-
panying images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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